Genturn Life Secures Tens of Millions in RMB in Angel Funding Led by CAS Star and Sazbio to Advance AI-Driven Rejuvenation Therapies

Investment Circle (ID: pedaily2012) February 4th news, according to Arterial Network reports, recently, Genturn Life Sciences, a company engaged in the development of regenerative anti-aging innovative drugs, announced the completion ofTens of Millions of Angel RoundFinancing, this round of financing was led byCo-led by Zhongke Chuangxing and Cygnus CapitalInvestment in the IIT research of partial reprogramming core pipelines and the construction of an AI molecular design platform. Previously, the U.S.-based Life Biosciences announced that its first product, ER-100, from the partial reprogramming technology pipeline received FDA clinical approval (IND), marking the official entry of epigenetic reprogramming technology for reversing aging into the clinical validation stage.

Genturn Life Sciences (Shenzhen Genturn Life Co., Ltd.) is an innovative biotechnology company focused on AI-driven aging reversal therapies. Dedicated to developing cutting-edge treatments for age-related diseases through advanced aging reversal technologies, the company’s core team consists of scientists from top institutions such as Stanford, Cornell, and the National University of Singapore, with deep expertise in areas like cellular reprogramming, RNA therapy, and AI-driven drug design. The founder, Dr. Xiangjun Zhou, has extensive experience in cell biology and epigenetics.

The company has established a comprehensive intellectual property system, owning multiple core patents covering key technical fields such as partial reprogramming factor design, AI algorithms, circular RNA design, preparation processes, cell-specific carriers, and delivery systems. Genturn Life Sciences is committed to becoming a global leader in the field of aging reversal therapy, with the mission of "extending the healthy lifespan of every individual."

Genturn chooses to reconstruct from the molecular bottom layer, relying on its self-developed AI protein design platform. Using genetic algorithms, it performs engineered modifications of the Yamanaka transcription factors to regulate phase separation functions. This has led to the development of a combination of transcription factors that retain only the ability of the first stage of reprogramming — "initiation-stage reprogramming" — for use in creating in vivo partial reprogramming products aimed at reversing aging. Compared with similar products in the United States, this approach improves both safety and efficacy.

Compared with similar technologies, Genturn has two advantages: stronger risk source control and more precise state capture. The former effectively avoids potential safety hazards that may cause changes in the spatial structure of the genome by micro-regulating the structure of transcription factors, reducing the risk of tumorigenesis from the source. The latter, based on the company's unique IPR (Initial Phase Reprogramming) technology, successfully locks the reprogramming process within a "safe window" that ensures high efficiency in rejuvenation without losing cellular identity, achieving precise resetting of epigenetic age.

Dr. Detu Zhu, Vice President of R&D at Genturn Life Sciences, stated:Aging is not an irreversible one-way process; the functional decline and diseases it brings have become the frontier that modern medicine urgently needs to conquer. At Genturn, we are committed to transforming the cutting-edge science of aging biology into new therapies that can effectively improve human health.

This is a challenging path, but one of extraordinary significance. We believe that interventions targeting the fundamental mechanisms of aging will bring new hope to disease areas lacking effective treatments. With unwavering determination and a scientifically pragmatic approach, our team is fully committed to achieving this goal.